The researchers found that the standardized mean differences for change in urticaria symptoms were –1.05, –1.07, –0.77, and –0.59 for ligelizumab 72 and 240 mg and omalizumab 300 and 600 mg, respectively. There were no significant differences observed in treatment unacceptability. Based on network estimates, the most efficacious treatments with respect to benefits and harms were achieved with ligelizumab 72 or 240 mg (large beneficial effect) and omalizumab 300 or 600 mg (moderate beneficial effect).

"Head-to-head trials with high methodologic quality and harmonized design and outcome definitions are needed to help inform subsequent international guidelines for the management of CSU," the authors write.

Abstract/Full Text (subscription or payment may be required)